Janssen gets EC approval for expanded use of IMBRUVICA (ibrutinib) plus rituximab to treat CLL EP News Bureau Sep 7, 2020 Data from Phase 3 E1912 study showed previously untreated patients aged 70 years or younger treated with ibrutinib plus rituximab…
